Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Aimmune Therapeutics  (Stock symbol: AIMT ) Acquired by Nestlé Health Science (2020 $ 2,000,000,000 )

8000 Marina Boulevard Suite 200
Brisbane, CA 94005
USA
(650) 614-5220
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) Kathryn Falberg (Jazz Pharmaceuticals Former CFO) Patrick G Enright (Longitude Capital Managing Director) Stacey D Seltzer (Aisling Capital Partner) Greg Behar (Nestlé Health Science) Brett Haumann (Theravance Biopharma Chief Medical Officer & SVP Clinical Development) Mark Iwicki (Kala Pharmaceuticals Executive Chairman) Mark McDade (Qiming Venture Partners Managing Partner)
Former outside board: James B Tananbaum (Foresite Capital CEO & Managing Director) Bryan L Walser (Aimmune Therapeutics Founder) Joon Yun (Palo Alto Investors President)
Company

Business description: Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies.
Capital

Rounds: 6
Recent Fundings: Feb 2020   Nov 2018
Capital raised: 696.7M
Last Round: 200.0M
Ownership: Acquired by Nestlé Health Science (2020 $ 2,000,000,000 ) Ipo Filing
Stock Symbol: AIMT
VCs include: Palo Alto Investors Aisling Capital Foresite Capital ;  Longitude Capital Management ;  RA Capital Management ;  Fidelity Management & Research SoftBank Vision Fund ;  Nestlé Health Science ;  existing investor: Nestle Health Science;  DNA Capita
Private equity: Adage Capital Management ;  LIAN Group

Last Tweets


 

Last Mentions


Overview
Record updated: Jul 2022
Sector: Biotech
Year Founded: 2011
Headcount: 401-500 as of Jul 2022
Rounds: 6
Recent Fundings: Feb 2020   Nov 2018
Capital Raised: 696.7M
Last Round: 200.0M
Ownership: Acquired by Nestlé Health Science (2020 $ 2,000,000,000 ) Ipo Filing
Stock Symbol: AIMT